Abstract: Non-invasive Ocular Drug Delivery Insert Technology. The invention concerns an ocular insert which is a new biocompatible polymer-based controlled drug delivery system (CDDS) applicable to a variety of drugs and other compounds for the treatment of different ocular pathologies. This ocular insert allows releasing of at least one drug under suitable concentration levels during suitable periods of time. The device may be inserted in the lower or upper fornix conjunctiva, in a non-invasive way, meaning that the patient will be able to place the device himself, without intervention of medical specialized staff. The insert of the invention will release the drug in such a controlled rate that will allow the drug release up to 300 days by either a “Fickian” or a linear profile according to the intend purpose or pathology.

Abstract: A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance.

Abstract: A stabilized active oxygen-generating antiseptic composition is disclosed including at least one of an antiseptic mixture or an antiseptic polymer. The antiseptic mixture includes a persulfate distributed in a matrix of a sulfate wherein the antiseptic composition is characterized by a ratio of the sulfate to the persulfate of at least 8:2. The antiseptic polymer is formed by the reaction of a sulfate, a persulfate, and amino acid in a reaction solution having a ratio of the sulfate to the persulfate of at least 6:4 and a ratio of the amino acid to the sulfate and the persulfate combined of 1:2 to 2:1. An antiseptic irrigation solution is disclosed including the antiseptic composition dispersed in a solvent. An antiseptic article is disclosed including an article and at least one of the antiseptic composition or an antiseptic coating formed from the antiseptic composition disposed on a surface of the article.

Abstract: A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance.

Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Abstract: A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance.

Abstract: The present invention provides a composition for preventing, ameliorating, alleviating or treating dermatitis comprising exosomes derived from adipose-derived stem cells as an active ingredient. The composition of the present invention is able to act against dermatitis-inducing multiple cytokine targets, and thus be widely applied against dermatitis caused by various factors and effectively suppress and alleviate dermatitis.

Abstract: A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance.

Abstract: A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues. The systemic vasodilation of a mammal may be increased via a topical application of an appropriate nitric oxide producing substance.

Abstract: Disclosed herein are lipid emulsified systems containing antihistamines. Also disclosed herein are pharmaceutical compositions containing the lipid emulsified systems and other chemotherapeutic agents, and methods of chemoprevention and cancer treatment with compositions containing the lipid emulsified systems.

Abstract: Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.

Abstract: The present invention relates to a hair cosmetic composition, especially for washing and/or conditioning hair, comprising surfactants and an oil-in-water emulsion that comprises: a silicone mixture comprising a trialkylsilyl terminated dialkylpolysiloxane and an amino silicone; a mixture of emulsifiers comprising one or more nonionic emulsifier, wherein the mixture of emulsifiers has a HLB value from 10 to 16; and water. The invention also relates to a process for the cosmetic treatment of hair, preferably for washing and/or conditioning hair, using this composition.

Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.

Abstract: Provided are stem cell biomimetic microparticles comprised of at least one stem cell-derived paracrine polypeptide or growth factor embedded in a polymer core particle that further comprises an outer layer of at least one fragment of a cell membrane of a stem cell disposed on the core particle. The polymer core may be constituted of any biocompatible and biodegradable polymer or copolymer, or a combination thereof that allows the embedding of the paracrine factors and their prolonged release from the core. The core and hence the microparticles can be biodegradable, allowing eventual elimination from the recipient animal or human subject. The core particles are sized to allow both transport through blood vessels and extravasation from the blood vessels into the surrounding tissues. The core particle may further include at least one polypeptide or peptide growth factor to induce the generation and proliferation of a population of stem cells.

Abstract: The invention relates to a cosmetic active ingredient comprising at least one Metschnikowia reukaufii extract, and the use of same for the cosmetic treatment of the skin, in particular for improving the radiance of the complexion by acting on the skin microbiota. The active ingredient is effective on mature skin. The invention also concerns compositions comprising the cosmetic active ingredient and a cosmetic method for treating the skin using these compositions.

Abstract: A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.

Abstract: The present invention relates in one aspect to the discovery of novel mesoporous silica nanoparticles (MSNs) templated around and comprising benzalkonium chloride (BAC). In certain embodiments, the BAC-SiO2 mesoporous nanoparticles are capable of sustained release of BAC under acidic conditions, thereby acting as a long release antimicrobial agent. In other embodiments, the BAC-SiO2 mesoporous nanoparticles can be incorporated into a variety of consumer products as an antimicrobial agent additive, including for example, but not limited to, surgical dressings, bandages, deodorants, soaps, facial cleansers and industrial cleaners.

Abstract: The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

Abstract: A cosmetic composition including exosomes derived from Galactomyces as an active ingredient is provided for skin regeneration, skin elasticity improvement or skin wrinkle reduction. The cosmetic composition has excellent effects on skin regeneration, skin elasticity improvement and/or skin wrinkle reduction.

Abstract: Multilayer beads for pharmaceutical use having a drug-in-polymer layer are disclosed. The disclosed multilayer beads for pharmaceutical use have (a) a core particle; (b) an optional barrier layer coated on the surface of the core particle; (c) a drug-in-polymer layer coated on the surface of the core or the barrier layer, (d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and (e) optionally one or more outer layers external to the drug-in-polymer layer or the sealant layer. The drug-in-polymer layer consists essentially of (i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and (ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or a mixture thereof. The drug-in-polymer layer may be solid dispersion of the drug in the polymer.